.svg){kind=small}
Jul-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Where to Buy
Proof is stocked at 122 licensed dispensaries across California and Maine, 121 of them in California, with the deepest coverage in Santa Rosa, San Francisco, Los Angeles, Sacramento, and San Jose. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
In July 2026, Proof concentrated 58.23% of sales in Tincture & Sublingual, where year-over-year declined 1.53% and month-over-month fell 8.23%, while Capsules rose 7.83% MoM despite a 9.34% YoY drop to 26.10% share. Topical held 9.63% share with a 3.69% YoY increase but a 14.27% MoM decline, and Concentrates contracted 52.18% YoY and 20.29% MoM to 5.42% share; Beverage remained marginal at 0.62% share with a 72.32% MoM rebound off a 69.44% YoY fall. With brand sales down 9.56% YoY and average price up 7.31% YoY to $39.57, the pattern implies a pivot toward core wellness formats while retreat from inhalables and niche beverage limits upside in July 2026.
Ranking 9th in Tincture & Sublingual in California places Proof’s anchor category in the middle of the pack, yet the 8.23% MoM dip there alongside a 7.83% MoM lift in Capsules suggests share is rebalancing between two premium-priced, wellness-oriented formats. The 14.27% MoM pullback in Topical and the 20.29% MoM drop in Concentrates reduce exposure to faster-cycling potency plays, while a 72.32% MoM Beverage bounce from just 0.62% share is too small to alter mix. The implication is that Proof’s positioning is consolidating around tinctures and capsules at higher price points, trading short-term volume volatility for steadier wellness-led differentiation within July 2026 category dynamics.
Competitive Landscape
Proof ranks #9 in California Tincture & Sublingual in July 2026, slipping 1 position year over year from #8 while dropping 3 positions since April 2026 when it peaked at #6; in contrast, Yummi Karma climbed to #1 from #2 with 15.99% YoY sales growth and ABX / AbsoluteXtracts advanced to #5 from #7 with 30.19% YoY growth, whereas Papa & Barkley fell to #2 from #1 alongside a -13.54% YoY decline and Care By Design slid to #4 from #3 with -13.46% YoY; this mix of upward momentum among value- and velocity-driven rivals alongside declines at legacy leaders implies Proof’s rank trajectory is drifting toward the second tier unless it reclaims share from the #5–#7 corridor.
Notable Products
CBD/THC 1:1 Balance Tincture (300mg CBD, 300mg THC, 15ml) posted the steepest decline in July 2026 at -16.3% MoM while dropping to rank 2, alongside sharper slides for CBD/THC 20:1 Tincture (300mg CBD, 15mg THC, 15ml) at -30.3% and High THC Tincture (1000mg THC, 15ml) at -29.3%. In contrast, CBD/THC 1:1 Bazillion Tincture Drops (1000mg CBD, 1000mg THC, 15ml) rose 26.1% MoM to hold rank 1 and captured $40,919, as the Topical at rank 10 fell -25.3% and the CBD Rich Tincture Drops at rank 8 declined -26.3%. With eight of the top ten in Tincture & Sublingual, the split between 1:1 gains and broader THC- or CBD-skewed declines implies Proof’s momentum is concentrating around balanced ratios rather than single-dominant cannabinoid profiles.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
